Tuesday, 20. January 2026 | Filed under
Company News
- Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthma
- Positive opinion from the European Patent Office strengthens patent protection of ATP-R13
- Progress significantly enhances the strategic attractiveness of ATP-R13 as a broadly applicable, disease-modifying therapy across multiple allergic indications
Atopia Therapeutics, a leader in the development of innovative, disease-modifying therapies for allergic and atopic diseases, today announced significant progress in the development of its lead compound ATP-R13. The Company has successfully generated new preclinical in vivo efficacy data supporting the potential of ATP-R13 as a novel oral treatment for atopic dermatitis, an allergic condition commonly known as eczema.
Read more…
Monday, 22. December 2025 | Filed under
Company News
Thursday, 11. December 2025 | Filed under
Company News
— First study participant dosed in U.S. trial with healthy volunteers and patients with peanut allergy
— Novel, human-derived, half-life extended tri-specific monoclonal antibody to prevent allergic reactions
Mabylon AG, a leader in the high-throughput discovery, engineering, and development of human-derived antibodies for the treatment of allergies, neurodegenerative diseases, and inflammation, today announced that the first healthy volunteer has been dosed in the first-in-human clinical trial evaluating MY006, a novel tri-specific monoclonal antibody for the prophylactic treatment of peanut allergy. MY006 is based on patient-derived antibodies and designed to provide a new approach for preventing allergic reactions in individuals with peanut allergy.
Read more…
